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Abstract 
BACKGROUND: Life expectancy among schizophrenic patients is 20% shorter than the general population. 
Currently, long-term use of antipsychotic drugs can induce metabolic symptoms, including weight gain, glucose 
intolerance, high blood glucose.  
AIM: This research aimed to investigate the fasting blood sugar level of a male patient with schizophrenia treated 
with flexible dose. 
METHODS: This research is an experimental study, unpaired numerical comparative analytic with non-probability 
consecutive sampling by recruiting 50 research subjects of men with male patients with schizophrenia. Every 25 
people were treated with aripiprazole, and another 25 subjects were treated with risperidone. The flexible dose on 
how doses are equated with bioequivalent doses between aripiprazole and risperidone was applied. Sampling 
was carried out in the inpatient and outpatient clinic of the psychiatric hospital Prof. Dr M. Ildrem Medan, North 
Sumatra, Indonesia, in a span of 6 months from January 2018 to July 2018. The diagnostic test used a Mini 
structured interview system International Statistical Classification of Diseases-10 (Mini-ICD 10) and the statistical 
analysis was involving Mann Whitney U Test.  
RESULTS: This research showed the mean of fasting blood sugar level in week 8 in the group receiving 
treatment with aripiprazole was 88.96 with a standard deviation of 4.33 and in the group receiving risperidone 
treatment was 102.80 with a standard deviation of 2.92. The results of the analysis using unpaired t-test in the two 
groups showed a significant difference in fasting blood sugar levels for men with schizophrenia in the group 
receiving aripiprazole treatment and the group receiving risperidone treatment in week 8 with a value of p < 0.001 
(p < 0.05). 
CONCLUSION: This research revealed that based on the equivalence of risperidone and aripiprazole dosage 
given to the male patients with schizophrenia, the treatment using risperidone can significantly increase the 
fasting blood sugar level compared to the aripiprazole treatment in week 8. 
 
 
 
Introduction 
 
The best treatment option for schizophrenia is 
the use of long-term antipsychotic drugs. It is currently 
documented that long-term use of antipsychotic drugs 
can induce metabolic symptoms, such as body 
weight, glucose intolerance, high blood glucose, and 
unhealthy blood lipid profiles, which are closely 
related to cardiovascular disease and diabetes [1].
 
Atypical antipsychotics are the most 
commonly prescribed class of schizophrenia drugs. 
The published evidence shows that these agents 
provide antipsychotic properties with a lower risk of 
extrapyramidal symptoms than other specific 
antipsychotic drugs. However, concerns about Extra 
Pyramidal Symptoms (EPS) have been replaced by 
other side effects, such as weight gain, glucose 
deregulation and dyslipidemia [2].
 
Glucose is a sugar contained in the blood 
formed from carbohydrates contained in food and 
stored as glycogen in the liver and skeletal muscles 
[3]. The presence of blood glucose in the body has a 
function to be used as fuel for metabolic processes 
and the most important energy source in the brain. 
Glucose in the blood can also be used as a parameter 
to determine the presence of diabetes mellitus [4].
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A study also explained that about gender, it 
was found that when compared with men, women with 
normal glucose tolerance have better levels of insulin 
sensitivity and cell-β function, but could be damaged 
by the level of injury. As well as sex-related, it is also 
said to be associated with using the glucose oral 
tolerance test that women have a higher impaired 
glucose tolerance level, while the disturbed fasting 
glucose level is higher in men. This is in addition to 
the influence of hormones and fat distribution also due 
to slower glucose absorption in women [5].
  
The right mechanism for diabetes mellitus 
which is associated with antipsychotics and various 
possible factors to increase levels of free fatty acids 
(FFAs) has been found to cause insulin resistance in 
skeletal muscle in vivo through reducing stimulation of 
insulin synthesis in muscle glycogen and glucose 
oxidation, which causes a decrease in glucose 
transport activity [6].
 
Atypical antipsychotic drugs are the first limit 
that can be given to almost all patients with psychotic 
disorders that have low side effects for metabolism. In 
some literature, there is still a potential relationship 
with the administration of risperidone to have a risk of 
weight gain, diabetes, hyperglycemia, lipid 
dysregulation [7].
 
One study showed that risperidone 
had lower levels of hyperglycemia and diabetes 
mellitus compared to other antipsychotic drugs, 
especially olanzapine. However, several other studies 
also concluded that risperidone has a risk of diabetes 
that is comparable to First Generation Antipsychotic 
(FGAS) [8].
 
Aripiprazole is different from most other 
antipsychotics due to partial agonists at D2 receptors 
and not antagonists. Aripiprazole does not have the 
pharmacological properties that usually associated 
with sedation, namely the cholinergic M1 (muscarinic 
cholinergic) and H1 (Histamine) and is therefore 
generally not soothing. Furthermore, there is little 
association of aripiprazole with dyslipidemia, 
increased fasting triglycerides, or insulin retention. 
The pharmacological properties that make 
aripiprazole different in their low metabolic risk are 
unknown but can be explained if aripiprazole cannot 
bind postulated receptors which mediate insulin 
resistance and hypertriglyceridemia [9].
 
A study conducted by Marusita and 
colleagues in 2007 in Japan using the first 
schizophrenia group which treated with monotherapy 
of risperidone and the control group. The metabolic 
changes in people with schizophrenia compared to 
the control group where among metabolic parameters 
showed that only fasting blood glucose which has 
significantly higher levels in the risperidone 
monotherapy schizophrenia group [7]. 
A study conducted by Robinson et al. (2015) 
that looked at a randomised comparison of 
aripiprazole and risperidone in the treatment of acute 
schizophrenia in the first three-month schizophrenic 
patients in this study found results in improved 
symptom relief on aripiprazole. However, the side 
effects of each drug were different, which is found to 
be more severe akathisia on aripiprazole compared 
with risperidone. Moreover, aripiprazole is also 
associated with better results for fasting glucose [10]. 
This research aimed to investigate the fasting 
blood sugar level of a male patient with schizophrenia 
treated with flexible dose. 
 
 
Methods 
 
Population and Demographics 
This study is an experimental study with non-
randomized pre-test and post-test design, and 
consecutive sampling method. The sampling was 
conducted in mental hospitals Prof. Dr Ildrem Medan, 
namely patients who come to the clinic and 
emergency department with inpatient status and 
fulfilling the inclusion and exclusion criteria [11].
 
Group 
I, is consisted of 25 men with schizophrenia who 
received treatment with aripiprazole, while group II 
consists of 25 men with schizophrenia who received 
risperidone treatment. The retrieval of the number of 
subjects in this study has been adjusted in advance 
with a large sample formula for the unpaired 
numerical scale group, according to the literature used 
in Indonesia [12].
 
In this study, the subject was obtained from a 
mental hospital Prof. dr. M. Ildrem Medan, North 
Sumatra, Indonesia, where this study lasted for 6 
months, from January 2018 to June 2018. Subjects 
were diagnosed with schizophrenia using diagnostic 
criteria and interviews structured using Mini ICD 10.  
 
Inclusion criteria 
Male schizophrenic patients aged 20-45 years 
old, the first patient affected by schizophrenia or 
schizophrenic patients who have already dropped out 
of treatment for 7 days, with a long illness below 5 
years, and having an ideal weight scale (body mass 
index) = 18.5-24.99, with a total PANSS 80-120 and 
PANSS-EC scores (Excited PANSS Component 
Scale = ≤ 15) with regard to each agitation score 
symptom being P4, P7, G4, G8, G14 = ≤ 4. 
 
Exclusion criteria 
Male subjects with schizophrenia who have 
other comorbid medical illnesses, organic mental 
disorders, or other psychiatric disorders, comorbid 
subjects with chronic and metabolic diseases and 
have a family history of DM, obesity, dyslipidemia, 
heart disease and other metabolic disorders, he found 
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history of use of prohibited substances and 
hypersensitive subjects to aripiprazole and 
risperidone. 
 
Procedure 
In this study, both groups of subjects in both 
men with schizophrenia who received aripiprazole 
treatment and groups of subjects in men with 
schizophrenia who received risperidone were given a 
flexible dose by first using equivalents between 
aripiprazole and risperidone. Schizophrenia found that 
the equivalent of aripiprazole with 1 mg olanzapine 
was 1.4 and the equivalent of risperidone with 
olanzapine was 0.4. Therefore, it can be concluded 
that 14 mg of aripiprazole is equivalent to 4 mg 
risperidone [13].
 
The dose increase in the aripiprazole 
group is carried out every 2 weeks, and risperidone is 
increased per 2-3 days, each group will stop if the 
dose has responded to PANSS totalling 50% and at 
week 8 the average dose for each subject group will 
be made. The aripiprazole subject group was the 
subject of Aripiprazole treatment and started with a 
dose of 10 mg/day, then the PANSS score will be 
measured the following week, if the PANSS score has 
not yet reached a response, the dose of Aripiprazole 
will be increased by 5 mg/day every two weeks until 
the response occurs. Maximum dose of 30mg. The 
risperidone group was subjects who received 
risperidone therapy.  
For men with schizophrenia in the first attack, 
the dose of risperidone will be raised titration, which 
begins with a dose of 2 mg/day and PANSS score will 
be measured every day and the dose of risperidone 
will be increased 1 mg/day until a response occurs. 
Especially for male subjects with schizophrenia who 
were not the first attack or discontinued the drug, then 
the dose of risperidone given was the last dose that 
responded. If the occurrence of side effects such as 
Parkinsonism during treatment is given 
trihexyphenidyl anticholinergic therapy at a dose of 6 
mg/day/oral in divided doses, a maximum of 15 mg. If 
there are acathic side effects, the subject will be given 
lorazepam 2 mg in divided doses, a maximum of 6 mg 
in divided doses, and if the drug is still not able to 
overcome these side effects, the subject will be 
dropped and given other class of drugs as indicated 
for the benefit of the subject. 
This study was treatment analysis so that if a 
drop out occurs, the subject will be replaced with a 
new one. The drop out criteria was subjects who have 
not succeeded in completing treatment for 8 weeks, 
as well as unresolved drug side effects. 
Fasting blood glucose sampling on all 
subjects was collected starting from baseline (week 0, 
i.e. before administration of the drug), and every week 
until the 8th week. Blood samples were taken at 6:00 
a.m. to 8:00 p.m., where previous patients fasted at 
least 10-12 hour. 
Table 1: Sample distribution on demographic characteristics of 
research subjects 
 Male patients with 
schizophrenia who were 
treated with aripiprazole, n = 
25 
Male patients with 
schizophrenia who were 
treated with Risperidone, n = 
25 
p 
Age (Mean ± SD) 33.520 ± 4.718 33.120 ± 4.969 0.772a 
Educational 
Background 
Elementary-Junior 
High School 
Senior High School 
 
11 (44.0%) 
 
14 (56.0%) 
 
 
8 (32.0%) 
 
17 (68.0%) 
0.561b 
Marital Status 
Married 
Single 
 
7 (28.0%) 
18 (72.0%) 
 
7 (28.0%) 
18 (72.0%) 
0.1000b 
Job Status 
Work 
Unemployed 
 
9 (36.0%) 
16 (64.0%) 
 
7 (28.0%) 
18 (72.0%) 
0.762b 
Illness Duration 
Median (minimum-
maximum) 
 
3.000 (1.00-4.00) 
 
3.000 (1.00-4.00) 
0.844-
0.422c 
 
Hospitalisation History 
(year) 
≤ 3 
> 3 
 
 
13 (52.0%) 
12 (48.0 %) 
 
 
13 (52.0%) 
12 (42.0%) 
0.1000b 
Onset Age (Mean±SD) 30.84 ± 4.259 
 
33.60 ± 4.481 0.847a 
Fasting Blood Sugar 
Levels (week 0) 
Median (minimum-
maximum) 
 
 
76.00(70.00-86.00) 
 
 
74.00 (70.00-86.00) 
0.310-
0.155c 
Body Mass Index 
Week 0 (Mean ± SD) 
8th week (Mean ± SD) 
 
21.719 ± 1.563 
22.018 ± 1.714 
 
21.367 ± 1.140 
21.960 ± 1.355 
 
0.368a 
0.896a 
PANSS Score (week 0) 
(Mean ± SD) 
 
PANSS Score (8th 
week) 
Median (minimum-
maximum) 
 
104.200 ± 6.745 
 
 
37.00 (36.00-40.00) 
 
103.840 ± 6.920 
 
 
37.00 (35.00-41.00) 
 
0.853a 
 
 
0.537-
0.269c 
a Unpaired t-test Tidak Berpasangan; b chi-square test; c Mann Whitney U test. 
 
Statistical Analysis 
Data were analysed using SPSS version 21 
statistical test. Normality tests were conducted on the 
data of each group using the Saphiro-will test because 
the number of subjects in each group is smaller than 
50. For unpaired numerical comparative groups two 
groups, if the distribution of data is normally 
distributed so that the unpaired T-test is carried out. If 
the distribution of data is not normally distributed then 
the data transformation is carried out, after that the 
normality test is conducted again, if the data is not 
normally distributed then the analysis carried out is 
the Mann-Whitney U test, [12]
 
while for the 
comparative numerical group the two groups are 
paired, if the distribution of data is normally distributed 
then a paired T-test will be carried out. If the 
distribution of data is not normally distributed, then 
data transformation will be carried out. After that the 
normality test was finished; if the data is still not 
normally distributed then the analysis carried out is 
the Wilcoxon test [12]. 
 
 
Results 
 
This research was the first study ever 
conducted in Indonesia regarding fasting blood sugar 
levels at week 8 in male patients with schizophrenia 
who recruited 50 subjects, namely subjects with 
treatment for aripiprazole and risperidone treatment 
with 25 subjects each and with flexible dose by first 
paying attention to the dose bioequivalence in both 
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drug groups. And during this study, there were no 
subjects who dropped out and experienced side 
effects from the administration of aripiprazole and 
risperidone. 
Demographic data in both groups of subjects 
are described in Table 1. It is found that there were no 
differences in demographic characteristics in the two 
groups of subjects with the majority value (p > 0.05). 
 
Figure 1: The line chart of the average subject group dosage for 
treatment with aripiprazole and risperidone 
 
Based on Figure 1, the average dosage in the 
group of men with aripiprazole is 17.6 while in the 
group of men with risperidone is 5.04. This is 
equivalent to 17.5 aripiprazole is comparable to 5 mg 
risperidone. 
 
Figure 2: The line chart of the average of bio-equivalence dosage of 
the risperidone treatment group to the aripiprazole treatment group  
 
Figure 2 shows the average of risperidone 
dosage is started to be equivalent to aripiprazole at 
week 5. Moreover, Figure 1 and Figure 2 shows 
equivalence for both treatment groups which can be 
seen at week 5. This is due to differences in half-life in 
both drugs and titration properties from different 
aripiprazole and risperidone. 
Table 2: The normality test result of fasting blood sugar level in 
male patients with schizophrenia who were treated with 
aripiprazole between week 0 and week 8 
Aripiprazole Treatment Subjects (n) p 
Blood Sugar Level-week 0 25 0.251* 
Blood Sugar Level-8
th
 week 25 0.997* 
Blood Sugar Level Difference between a 1
st
 week and 8
th
 
week 
25 0.940* 
*Shapiro-Wilk p > 0.05. 
 
Based on Table 2 above, the data are 
normally distributed, so that, a paired t-test can be 
performed. 
Table 3: The result of complete paired t-test for aripiprazole 
 Mean ± SD Difference ± SD IK 95% p 
Blood Sugar Level-
week 0 (n = 25) 
76.24 ± 4.48 12.72 ± 3.40 11.31-14.12 < 0.001* 
Blood Sugar Level-8
th
 
week (n = 25) 
88.96 ± 4.33    
*Paired t-test, p < 0.05. 
 
Table 3 shows that the average fasting blood 
sugar level at week 0 that received treatment for 
aripiprazole was 76.24 ± 4.48 and the mean fasting 
blood sugar level at week 8 receiving treatment with 
aripiprazole was 88.96 ± 4.33. The differences in 
mean fasting blood sugar levels of week 0 and week 8 
are 11.31 to 14.12. The results of the analysis using 
paired t showed a significant difference in fasting 
blood sugar levels in men with schizophrenia who 
received aripiprazole treatment at week 0 and week 8 
with p values < 0.001 (p < 0.05). 
Table 4: The normality test result of fasting blood sugar level in 
male patients with schizophrenia who were treated with 
risperidone between week 0 and week 8 
Risperidone Treatment Subjects (n) p 
Blood Sugar Level-week 0 25 0.002* 
Blood Sugar Level-8
th
 week 25 0.311* 
Blood Sugar Level Difference between week 0 and 8
th
 
week 
25 0.142* 
*Shapiro-Wilk p > 0.05. 
 
Based on Table 4 above, the data are 
normally distributed, so that, a paired t-test can be 
performed. 
Table 5: The result of complete paired t-test for risperidone 
treatment 
 Mean ± SD Difference ± SD IK 95% p 
Blood Sugar Level-
week 0 (n = 25) 
74.84 ± 5.11 27.96 ± 4.11 26.26 – 29.66 < 0.001* 
Blood Sugar Level-8
th
 
week (n = 25) 
102.80 ± 2.91    
*Paired t-test, p < 0.05. 
 
In Table 5 shows that the average fasting 
blood sugar level at week 0 who received risperidone 
treatment was 74.84 ± 5.11 and the mean fasting 
blood sugar level at week who received risperidone 
treatment was 102.80 ± 2.91 difference in mean 
fasting blood sugar levels of week 0 and week 8 26.26 
to 29.66.  
The results of the analysis using paired t 
showed a significant difference in fasting blood sugar 
levels in men with schizophrenia who received 
risperidone treatment at Week 0 and Week 8 with p 
values < 0.001 (p < 0.05). 
Table 6: The normality test result of fasting blood sugar level 
between the group treated with aripiprazole and risperidone on 
week 8 
 Treatment Subjects (n) p 
Blood Sugar Level-8
th
 
week 
Aripiprazole 25 0.977* 
Risperidone 25 0.311* 
*Shapiro-Wilk p>0.05. 
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Based on the result above, the data are 
normally distributed (p > 0.05). Therefore, an unpaired 
t-test can be performed. 
Table 7: The difference of fasting blood sugar level between 
the group treated with aripiprazole and risperidone on week 8 
Treatment Mean ± SD Mean Difference (IK 95%) p 
Aripiprazole 88.96 ± 4.33 -13.84 (11.74-15.94) < 0.001* 
Risperidone 102.80 ± 2.92   
*Unpaired t-test, p < 0.05. 
 
Table 7 shows the mean of fasting blood 
sugar level on week 8 in the group receiving treatment 
with aripiprazole is 88.96 with a standard deviation of 
4.33 and in the group that received treatment for 
risperidone is 102.80 with a standard deviation of 
2.92. The results of the analysis using unpaired t-test 
in the two groups showed a significant difference in 
fasting blood sugar levels for men with schizophrenia 
in the group receiving aripiprazole treatment and the 
group receiving risperidone treatment on week 8 with 
a value of p < 0.001 (p < 0.05). 
 
Figure 3: The line chart of the mean of fasting blood sugar level 
between groups treated with aripiprazole and risperidone 
 
Based on Figure 3 above, it shows that there 
was no increase in fasting blood sugar levels in the 
initial week. However, at week 8 the increase in 
fasting blood sugar levels showed a significant 
difference in both groups. Where fasting blood sugar 
levels in the group of men with schizophrenia who 
received risperidone treatment experienced an 
increase compared to the group of men with 
schizophrenia who received treatment for aripiprazole. 
Moreover, by using a flexible dose of 
bioequivalent doses, the development of the PANSS 
score is a benchmark in increasing doses and to pay 
attention to the level of development of treatment. As 
well as stopping the increase in dosage on the 
PANSSS score which reaches a 50% decrease in 
change, as a sign that the maximum response has 
occurred. In other words, this study also puts a 
concern to the treatment response too. 
In Figure 4, the PANSS score in both groups 
of subjects achieved a 50% loss in the PANSS score 
faster in subjects of the group of men with 
schizophrenia who received risperidone treatment.  
 
Figure 4: The PANSS Score between the group treated with 
aripiprazole and risperidone 
 
Furthermore, a subgroup test was also carried 
out between blood sugar levels and the dose of the 
drug as a secondary outcome which is an additional 
or supportive outcome, intended only for whether 
there are additional effects due to the intervention 
studied in addition to the main effects. But this is only 
an illustration and cannot be drawn as a conclusion 
(Table 8) [14]. 
Table 8: The difference in fasting blood sugar level based on 
dosages 
Treatment Dosages Blood Sugar Level (Mean ± SD) p 
Aripripazole 15 mg (n = 12) 
20 mg (n = 13) 
88.417 ± 3.423 
89.462 ± 5.125 
0.558 
Risperidone 4 mg (n = 11) 
6 mg (n = 14) 
103.090 ± 2.773 
102.571 ± 3.106 
0.668 
 
From Table 8 above, it can be seen that the 
average fasting blood sugar level based on the dose 
of aripiprazole with a dose of 15 mg obtained was 
88.417 ± 3.423, whereas fasting blood sugar levels at 
a dose of 20 mg obtained was 89.462 ± 5.125. The 
fasting blood sugar level of the risperidone group with 
a dosage of 4 mg was 103.090 ± 2.773, while the 
average fasting blood sugar level at a dose of 6 mg 
obtained was 102.57 ± 3.106. Since the p-value was 
more than 0.05, it can be inferred that the dose does 
not provide a significant difference in fasting blood 
sugar levels. 
 
 
Discussion 
 
Table 1 shows the demographic 
characteristics of each group. The mean based on 
age in the group that received treatment for 
aripiprazole is 33.520 years with a standard deviation 
of 4.718 years. For that receiving risperidone 
treatment, the mean based on age was 33.120 years 
with a standard deviation of 4.969 years. The highest 
education level in the treatment group that received 
Aripiprazole and risperidone was Senior High School 
and Higher Education with the number of 14 subjects 
(56.0%) in the aripiprazole group and 17 subjects 
(68.0%) in the risperidone group respectively. The 
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most marital status in each group was not married 
with 17 (72%) in the aripiprazole and risperidone 
groups. The highest occupational history in the 
treatment group that received aripiprazole and 
risperidone was unemployed, each of 16 subjects 
(64.0%) in the aripiprazole group and 18 subjects 
(72.0%) in the risperidone group. The duration of 
illness in the treatment group of aripiprazole and 
risperidone is that they have a median value of 3.000 
with the same minimum-maximum limit in the two 
groups of 1.00-4.00. The fasting blood sugar level at 
week 0 baseline or before administration of therapy of 
the aripiprazole and risperidone treatment groups 
were having an equal median value of 76.00 with the 
same minimum-maximum limit in the 70.00-86.00 
groups. The mean BMI-Week 0 (Baseline) in the 
group receiving aripiprazole treatment was 21.719 ± 
1.563 and in the group receiving risperidone treatment 
was 21.367 ± 1.140. The mean pass score of 0 
(before therapy) in the aripiprazole group was 104.200 
with a standard deviation of 6.745 and the mean in the 
103.840 group with a standard deviation of 6.920. The 
results of the analysis using unpaired t-test in the two 
groups showed a significant difference in fasting blood 
sugar levels for men with schizophrenia in the group 
receiving aripiprazole treatment and the group 
receiving risperidone treatment on Week 8 with a 
value of p < 0.001 (p < 0.05). Where in the 8th week, 
fasting blood sugar levels in the group of men with 
schizophrenia who took risperidone treatment were 
higher than in the group of men who used the 
treatment of aripiprazole. It’s by Wani, et al., (2015), 
discovered that the use of aripiprazole and risperidone 
increase the fasting blood sugar. However, the 
significant difference between aripiprazole and 
risperidone usage was observed at week 14 [15]. 
In conclusion, this study showed that based 
on flexible dose with equalising of bio-equivalent 
doses between the dosage of aripiprazole and 
risperidone in men with male schizophrenia who were 
treated with risperidone is tend to experience more a 
significant increase in fasting blood sugar levels 
compared with people receiving treatment for 
aripiprazole at week 8. 
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